natgillin/translations-raw huggingface dataset:
The control device of claim 8, wherein diazinon is present in an amount of from 40 % to 50% of the total weight of the ear tag, coumaphos is present in an amount of from 5 % to 15% of the total weight of the ear tag, cellulose fiber is present in an amount of from 5 % to 15% of the total weight of the ear tag, and polyvinyl chloride is present in an amount of from 35 % to 45% of the total weight of the ear tag. 
Kontrolni uređaj u skladu s patentnim zahtjevom 8, naznačen time što je diazinon prisutan u količini od 40% do 50% od ukupne težine ušne markice, kumafos je prisutan u količini od 5% do 15% od ukupne težine ušne markice, celulozno vlakno je prisutno u količini od 5% do 15% od ukupne težine ušne markice, a polivinil-klorid je prisutan u količini od 35% do 45% od ukupne težine ušne markice.
In the case of a post-emergence treatment of the plants, the herbicidal mixtures or compositions according to the invention are preferably applied by foliar application. 
U slučaju tretmana biljaka poslije nicanja, herbicidne smjese ili kompozicije prema izumu se poželjno primjenjuju folijarnom primjenom.
The process of claim 15, wherein the stainless steel consists of an austenitic stainless steel and the second composition consists of HNO3 and HF, and wherein the second composition consists of about 5 g/L to about 25 g/L HF. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što nehrđajući čelik sadrži austenitni nehrđajući čelik, a druga smjesa sadrži HNO; i HF, te gdje je koncentracija HF u drugoj smjesi u rasponu od 5 g/l do 25 g/l.
or a pharmaceutically acceptable salt thereof. 
CH, ili njegova farmaceutski prihvatljiva sol ili solvat.
It was then neutralized with sodium hydroxide up to a pH of 7.5-8.5 and then cooled down to 25°C. The final content of dry substance amounted to 50%. 
Neutraliziramo s natrijevim hidroksidom od pH 7,5 do 8,5 te ohladimo na 25%C,Konačni udio suhe tvari je 50 %.
Use according to claim 1 where the phosphodiesterase (PDE) 4 inhibitor is rolipram or its physiologically acceptable salts. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je inhibitor (PDE) 4 fosfodiesteraze rolipram ili njegove fiziološki prihvatljive soli.
The supply system requires an electric power source; typically, this source consists of the mains electrical system; in addition, a battery (or a similar component) may advantageously be provided so that the apparatus is operational even when there is no mains power (neither the electrical supply system nor the electric power sources are illustrated in the figures). 
Sustav za napajanje zahtjeva izvor električne energije; tipično je da se taj izvor sastoji od sustava električne mreže; dodatno tome može biti na povoljan način predviđena baterija (ili neka slična komponenta) tako da uređaj može raditi čak i kada nema napajanja iz mreže (na slikama nisu prikazani niti sustav električnog napajanja niti izvori električne energije).
The pharmaceutical composition of claims 1 and 8, wherein the pharmaceutical composition is a solid dosage form which takes the form of a bilayer tablet. 
Farmaceutski pripravak prema zahtjevima 1 i 8, naznačen time što je navedeni farmaceutski pripravak u čvrstom obliku koji je formuliran kao dvoslojna tableta.
A modified capsular saccharide comprising a blocking group at a hydroxyl group position on at least 80% of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia): 
Modificirani saharid iz kapsule, koji sadrži blokirajuću skupinu na položaju hidroksilne skupine u najmanje 80% monosaharidnih jedinica odgovarajućeg nativnog saharida kapsule, gdje blokirajuća skupina ima formulu (Ia):
After 18 h diethylacetylenedicarboxylate (6.0 mL, 37.5 mmol) was added and stirred for additional 3 days and concentrated. 
Poslije 18 sati dodan je dietilacetilendikarboksilat (6.0 mL, 37.5 mmol) i smjesa je miješana još 3 dana i koncentrirana.
The compositions described herein can be administered to an individual (such as human) via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što se pripravak daje putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, mtratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili inhalacijskog puta primjene.
A monoclonal antibody capable of binding to human GDF-15, or an antigen-binding portion thereof capable of binding to human GDF-15, wherein: 
Monoklonsko antitijelo koje se može vezati na humani GDF-15, ili njegov dio koji se veže na antigen, a koji se može vezati za humani GDF-15, pri čemu:
A pharmaceutical composition comprising a tumour associated peptide according to any one of Claims 1 to 3, a nucleic acid according to Claim 4 or 5 or an expression vector according to Claim 6 and a pharmaceutically acceptable carrier, preferably in the form of a cancer vaccine, optionally comprising at least one suitable adjuvant. 
Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te Tarmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
The groove structures can optionally also be disposed in both the mutually facing surfaces of the two plates which are relevant here and which are joined to each other. 
Prema potrebi, brazdaste strukture se mogu nalaziti u objema površinama dviju ploča koje su ovdje važne, koje su okrenute jedna prema drugoj i koje su spojene jedna s drugom.
The S-deprotected peptide can be isolated from the reaction mixture by addition of an anti-solvent, for example an aprotic non-polar solvent such as a hydrocarbon or an ether. 
S-deprotektirani peptid može se izolirati iz reakcijske smjese dodavanjem anti- otapala, na primjer aprotičnog nepolamog otapala kakav je ugljikovodik ili eter.
Use according to claim 1 where the phosphodiesterase (PDE) 4 inhibitor is roflumilast or its physiologically acceptable salts. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je inhibitor (PDE) 4 fosfodiesteraze roflumilast ili njegove fiziološki prihvatljive soli.
A method for the treatment of hyperlipidemia, dyslipidemia, lipid metabolism abnormality, arteriosclerosis, or type II diabetes mellitus, which comprises administering a pharmaceutically effective amount of the compound according to claim 30 to a warm-blooded animal. 
Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
The equipment 66 for the stacking is joined by a pressing equipment 67 for the respective beam-like block of wood. 
Oprema za slaganje 66 je povezana s opremom za prešanje 67 odgovarajućih komada od drva koji imaju oblik grede.
the impregnation of the strips of material with a hardenable fluid, the hardening of the impregnated strips of material into an end product. 
- < impregnacija traka od materijala (2, 2', 2",...) s fluidom koji se stvrdnjava,
The solid oral extended release pharmaceutical dosage form of anyone of claims 1 to 16, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec sadrži količinu od barem jednog aktivnog agensa u % (po težini) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije više od oko 10% točaka u odnosu na odgovarajuću količinu aktivnog agensa u % (po težini) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije skladištenja.
n is 0; R1, R2, and R3 are hydrogen; R6 is selected from the group consisting of hydrogen, alkyl, (NRCRD)sulfonyl, and arylalkyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
R, i R; su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; 1 Rc i Ry su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
a processor mechanism in operative communication with the camera; and at least one form, wherein the form includes thereon at least a first fiducial mark and a second fiducial mark, and wherein each of the first fiducial mark and the second fiducial mark has a measurable property that is essentially scale invariant; 
procesorski mehanizam u radnoj komunikaciji s kamerom; i najmanje jedan formular (400, 700), gdje formular u sebi sadrži u najmanju ruku prvu položajnu oznaku (401a,701a) i drugu položajnu oznaku (401b,701b);
A pharmaceutical composition comprising the oligomeric compound of claim 1, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant. 
Farmaceutski pripravak, naznačen time, da obuhvaća oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 16 1 farmaceutski prihvatljivo sredstvo za razrjeđivanje, nosač, sol ili adjuvant.
Preparation of the set-style yoghurt product: 
Broj objave europskog patenta:
The method of claim 34, wherein the inert gas is N2 or Ar and the reactive species is O2. 
Postupak prema zahtjevu 31, pri čemu je inertni plin N, ili AT 1 reaktivna vrsta je Oz.
The compound or salt of claim 1, wherein the compound is 6-chloro-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
3. - Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES 
Postupak za proizvodnju Linezolida sljedeće formule:
Absent the use of known ligands for the RUP25 receptor and radiolabels thereof, compounds of Formula (I) can be labelled with a radioisotope and used in an assay for evaluating the affinity of a test compound to the RUP25 receptor. 
Bez uporabe poznatih liganada za RUP25 receptor i njihovih radiološki označenih spojeva, spojevi Formule (I) mogu biti radiološki označeni sa radioizotopima i mogu biti korišteni u ispitivanjima evaluacije njihovog afiniteta prema RUP25 receptoru.
Method according to claim 2, characterised in that the shape of the side and back outlines of the body of the person is determined in a standing position of the body. 
Metoda prema zahtjevu 1, naznačena time što se oblik bočnih 1 stražnjih obrisa tijela osobe određuje u stojećem položaju tijela.
Use of a pharmaceutical composition as defined in at least one of the claims 1-12 for the preparation of a medicament for treating Type 2-diabetes in a patient, wherein the patient is a diet-treated Type 2-diabetic patient, a sulfonylurea-treated Type 2-diabetic patient, a far-advanced stage Type 2-diabetic patient and/or a long-term insulin-treated Type 2-diabetic patient. 
Farmaceutski pripravak za uporabu prema barem jednom od zahtjeva 1-11, naznačen time što dijabetes je dijabetes tipa 2. Uporaba farmaceutskog pripravka kao što je definirano u barem jednom od zahtjeva 1-11 naznačena time što je za dobivanje lijeka za liječenje dijabetesa kod pacijenta.
The filtrate was concentrated under reduced pressure to obtain {2-fluoro-3-[2-(piperidin-4-yl)pyrimidin-5-yl]phenyl}methanol (96 mg). Preparation Example 516 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da navedeni spoj je 2-fluoro-3-[2-(morfolin-4-iDpirimidin-5-il]benzil-karbamimidoilkarbamat, ili njegova sol.
The compound for the use of claim 1 wherein X and Y are taken together with the attached carbon to form carbonyl. 
Spoj za uporabu prema zahtjevu 1 gdje se X 1 Y uzimaju zajedno sa spojenim ugljikom da formiraju karbonil.
A method for treating a human with breast cancer, comprising administering to the human an effective amount of 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer or pharmaceutically acceptable salt thereof. 
HR P20130095 T1 Spoj prema zahtjevu 19, pri čemu je navedeni spoj3-(2,4-dihidroksi-5-izopropilfenil)-4-(N-metil-indol-5-i1)-5- merkapto-[1,2,4]triazol, ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The use according to claim 19, wherein the mood disorder is a depressive disorder. 
Uporaba prema zahtjevu 3, naznačena time, da se kod poremećaja raspoloženja radi o osnovnoj jakoj depresiji.
nitrosyl reduction (NR), in which an N,N-disubstituted-3-optionally substituted-4-nitrosyl aniline, 2, is reduced to form said N,N-disubstituted-1,4-diamino-5-optionally substituted benzene, 3: 
nitrozilna redukcija (NR) u kojoj se N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin, 2, reducira kako bi stvorio navedeni N,N-disupstituirani-1,4-diamino-5-opcionalno supstituirani benzen, 3:
The use of the system according to claim 7, wherein the polymer comprises acrylic acid monomers. 
Upotreba sustava u skladu sa zahtjevom 7, naznačena time, što polimer obuhvaća monomere akrilne kiseline.
A pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, wherein the pharmaceutical composition is in a dosage form which provides a) a metered nominal dose of aclidinium equivalent to 400 micrograms plus/minus 10% aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide, wherein the pharmaceutical composition is for inhalation. 
Farmaceutski pripravak koji sadrži aklidinij u obliku suhog praha farmaceutski prihvatljive soli u smjesi s farmaceutski prihvatljivim nosačem suhog praha, pružajući odmjerenu nominalnu dozu aklidinija jednaku 400 µg (plus/minus 10 %) aklidinijevog bromida za primjenu inhalacijom u liječenju kronične opstruktivne plućne bolesti.
is the side chain residue of an a-amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, Y-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, serine, threonine, tryptophan, tyrosine, and valine; 
R* je bočni lanac ostatka a-amino kiseline odabran od grupe koja se sastoji od alanin, arginin, asparagin, asparaginska kiselina, y-karboksiglutaminska kiselina, citrulin, cistein, glutaminska kiselina, glutamin, glicin, histidin, izoleucin, leucin, lizin, metionin, norleucin, norvalin, ornitin, fenilalanin, serin, treonin, triptofan, tirozin, i valin;
A compound of Formula (Ia) wherein: 
Spoj formule (la) naznačen time da:
The dAb of claim 9 that is formatted to increase its in vivo half-life. The dAb of claim 11, wherein the formatting comprises linking the dAb to polyethylene glycol (PEG) by a PEGylation reaction. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 2, naznačeno time, što formatiranje podrazumijeva vezivanje antitijela koje sadrži jednu imunoglobulinsku varijabilnu domenu za polietilen-glikol (PEG), reakcijom PEGilacije.
From the motherliq. was further 4.45 g (21%) product isolated (m.p. 
Iz matične tekućine izolirano je, nadalje, 4,45 g (21%) proizvoda (m.p.
These discharges generally last about 20 sec and occur spontaneously every minute when the animals are in a state of quiet wakefulness. 
Ova pražnjenja traju općenito oko 20 si do njih dolazi spontano svake minute kada su životinje u stanju mirne budnosti.
Polymer-bonded bodies of magnetic materials are obtainable from many different sources, such as from Group ARNOLD (Plastiform®) or from Materiali Magnetici, Albairate, Milano, IT (Plastoferrite). 
Tijela od magnetskih materijala spojenih polimerom mogu se nabaviti od brojnih različitih dobavljača, primjerice od Group ARNOLD (Plastiform*) ili Materiali Magnetici, Albairate, Milano, Italija (Plastoferrite).
1 schematically shows a process for producing sucrose and ethanol from sugar beet according to the invention. DETAILED DESCRIPTION OF THE INVENTION In the crystallisation process according to the invention, a solution of a water-soluble compound in a mixture of water and a solvent in which the water-soluble compound has a lower solubility than in water, is provided in a crystallisation vessel. 
Postupak kristalizacije spoja topivog u vodi iz otopine koji sadrži sljedeće korake: a) pružanje, u posudi za kristalizaciju, otopine spoja topivog u vodi u mješavini vode i otopine u kojoj spoj topiv u vodi ima slabiju topljivost nego u vodi; b) provođenje faze isparavanja mješavine kroz sorpcijsku zonu koja sadrži sorpcijsko sredstvo za vodenu paru kako bi selektivno adsorbiralo vodu iz faze isparavanja kako bi se u fazi isparavanja izdvojila voda i povećao udio otopine i vodom zasićenog vodenog sorpcijskog sredstva;
A compound of any one of claims 1 to 35 for use in a method of treating an HCV infection. The compound of claim 42 further comprising using one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 1 ili 2 koja dalje obuhvaća uporabu jednog ili dva dodatna spoja koji djeluju protiv HCV-a, prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili njegovom farmaceutski prikladnom soli ili sa spojem prema zahtjevu 2.
wherein each set of cassette oligonucleotides hybridises to one another to form a fluorescent quenched pair, wherein the fluorescent quenched pair has a Tm A; 
pri čemu svaki komplet oligonukleotida kasete hibridizira jedan sa drugim da bi formirao fluorescentni ugašeni par, pri čemu fluorescentni ugašeni par ima Tm A,
Even more preferably, said content exceeds 5 x EBC colour value, most preferably 10 x EBC colour value. 
Čak još poželjnije, spomenuti sadržaj prelazi 5 x EBC vrijednost boje, najpoželjnije 10 X EBC vrijednost boje.
The present invention relates to a process for manufacturing steel strips adapted to receive a surface coating which is resisting to oxidation by using anti-oxidizing elements such as aluminum, chromium or nickel, copper, etc., and in particular tin for producing tin-plate. 
Predmetni izum se odnosi na postupak za proizvodnju čeličnih traka koje su prilagođene za stavljanje površinskog zaštitnog sloja otpornog na oksidaciju primjenom antioksidirajućih elemenata kao što su aluminij, krom ili nikal, bakar, itd., a posebno kositar za proizvodnju bijelog lima.
A system according to claim 8, wherein the secondary identification card is also used for providing a unique identification code for authenticating communication of the two or more short-range phone interface units with the cellular base station via the cellular hub device. 
Sustav sukladno zahtjevu 4, naznačen time, da jedinstveni identifikacijski kod osigurava autentificiranu komunikaciju jedne od dvaju ili više jedinica sučelja telefona malog dometa putem mobilnog hub uređaja.
at least one but not necessarily all of said projecting lugs of each locking tumbler in said subset actually engaging with a corresponding code recess of said associated key upon fully inserting the latter into said key slot, and 
- - barem jedna ali ne nužno sve navedene izbočene stopice svakog čepića za zaključavanje u spomenutom podskupu nakon potpunog umetanja ključa u navedeni utor za ključ, zapravo sudjeluje s odgovarajućim kodnim udubljenjem navedenog pripadajućeg ključa,
Use of a kit comprising 
Uporaba garniture koja sadrži:
Device according to claim 6, characterised in that said non-stick material is selected from silicon derivatives, like for example silicon rubbers or silicon oils, thermoplastic polymers, polyolefins and derivatives and/or compounds and mixtures of such materials. 
Naprava u skladu s patentnim zahtjevom 6, naznačena time što se navedeni neljepljivi materijal bira između silikonskih derivata, poput primjerice silikonskih guma ili silikonskih ulja, termoplastičnih polimera, poliolefina 1 derivata i/ili spojeva i smjesa takvih materijala.
The set of panels as claimed in claim 1, wherein the first edge surface or the second edge surface comprises a recess. 
Komplet ploča prema patentnom zahtjevu 14, naznačen time što prva rubna površina ili druga rubna površina sadrže udubljenje (50).
The control system of claim 23, wherein the control schedule is generated according to a desired temporal profile of the monitored grid frequency. 
pri čemu je upravljački raspored generiran prema željenom privremenom profilu nadzirane mrežne frekvencije.
homogenizing the mixture from c), and cooling the emulsion obtained from d) during stirring. A method according to claim 1, wherein the total concentration of propylene glycol in the emulsion is from 20 to about 45% w/w. 
Emulzija ulje-u-vodi koja sadrži mometazon ili mometazon furoat i propilen glikol, te je koncentracija propilen glikola od 20 do 45% w/w, naznačena time da je udio mometazona ili mometazon furoata sadržan u neotopljenom obliku.
Total Number of Subjects 
Broj međunarodne objave:
The one or more digestive enzymes are, independently, derived from an animal source, a microbial source, a plant source, a fungal source, or are synthetically prepared. In some embodiments, the animal source is a pig pancreas. 
Oralno farmaceutski spoj za za uporabu sukladno bilo kojem od prethodnih zahtjeva, naznačena time da su probavni enzimi, nezavisno, dobiveni iz životinjskog izvora, mikrobiološkog izvora, biljnog izvora, izvora gljiva, ili su sintetski pripremljeni.
a variant of the peptide of a) that is to at least 80% identical to SEQ ID No. 
peptida koji se sastoji od odsječka aminokiseline u skladu sa SEQ ID br.
(viii) gastrointestinal diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(viti) gastrointestinalnih bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
FIG. 3E illustrates a method for operating a network service to enable a user to access a network service using multiple devices, according to one or more embodiments. 
Računalni sustav prema zahtjevu 8, gdje jedan ili više kontrolnih parametara kontroliraju koliko puta je korisniku dozvoljeno preskočiti poseban link za reprodukciju kada koristi mrežni servis sa skupom linkova za reprodukciju.
A compound according to claim 1, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. A composition comprising: 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
A skirt 68 projects from the first end 64 of the body 62. 
(32) Datum podnošenja prve prijave: 26.03.2007.